Anaheim Bio Launches with €40 Million Series A Financing to Advance ANA-1 for Calcium Pyrophosphate Deposition Disease into the Clinic

The Quick Take
Anaheim spun out of Alesta Therapeutics prior to its recent acquisition by BioMarin Financing provided by Droia Ventures, Frazier Life Sciences, RTW, Novartis Venture Fund, RV Invest and Thuja Capital Runway into 2028 with clinic entry in 2027 for ANA-1 LEIDEN, Netherlands, Nov. 5, 2026...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire General Business.
Related
Business
STAK Energy Signs Long-Term Agreement to Bring North Slope Natural Gas to Market
Agreement supports power development using previously stranded gas in northern Alaska ANCHORAGE, Alaska, Nov. 5, 2026 /PRNewswire/ -- STAK Energy Corporation…
Business
LA COMPAGNIE INTRODUCES YEAR-ROUND DIRECT BUSINESS CLASS SERVICE BETWEEN NEW YORK AND NICE
For the first time, the 100% Smart Business Class airline extends its New York–Nice service through the 2026–2027 winter season, offering the only direct…
Business
The RealReal Appoints Shar Dubey to Board of Directors
Former Match Group CEO Brings Deep Expertise in Technology, Digital Consumer Platforms and Scaling Global Businesses SAN FRANCISCO, Nov. 5, 2026 /PRNewswire/…
Local
NREF Announces Third Quarter 2026 Results, Provides Fourth Quarter 2026 Guidance
DALLAS, Nov. 5, 2026 /PRNewswire/ -- NexPoint Real Estate Finance, Inc. ("NREF" or the "Company") (NYSE: NREF) today reported its financial results for the…
